NYSE:HRC - Hill-Rom Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $115.29
  • Forecasted Upside: 24.80 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$92.38
▲ +1.31 (1.44%)
1 month | 3 months | 12 months
Get New Hill-Rom Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HRC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HRC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$115.29
▲ +24.80% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Hill-Rom in the last 3 months. The average price target is $115.29, with a high forecast of $125.00 and a low forecast of $100.00. The average price target represents a 24.80% upside from the last price of $92.38.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Hill-Rom.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/12/2020Raymond JamesLower Price TargetOutperform$115.00 ➝ $100.00High
i
10/1/2020KeyCorpLower Price TargetOverweight$138.00 ➝ $115.00Medium
i
9/29/2020Needham & Company LLCLower Price TargetBuy$129.00 ➝ $117.00Medium
i
9/21/2020Morgan StanleyLower Price TargetOverweight$112.00 ➝ $110.00Medium
i
9/16/2020Raymond JamesReiterated RatingBuyLow
i
9/1/2020Robert W. BairdInitiated CoverageOutperform$115.00High
i
8/3/2020Morgan StanleyLower Price TargetOverweight$123.00 ➝ $112.00High
i
8/3/2020Raymond JamesLower Price TargetOutperform$120.00 ➝ $115.00Medium
i
8/3/2020KeyCorpLower Price TargetOverweight$140.00 ➝ $138.00Medium
i
7/31/2020Needham & Company LLCLower Price TargetBuy$131.00 ➝ $129.00Low
i
5/4/2020UBS GroupLower Price TargetBuy$130.00 ➝ $125.00High
i
4/14/2020BarclaysReiterated RatingBuy$125.00Medium
i
3/27/2020Morgan StanleyLower Price TargetOverweight$138.00 ➝ $125.00Low
i
Rating by David Lewis at Morgan Stanley
3/17/2020BarclaysUpgradeEqual Weight ➝ Overweight$116.00High
i
1/24/2020Needham & Company LLCReiterated RatingBuy$131.00High
i
12/17/2019Morgan StanleyUpgradeEqual ➝ Equal Weight$113.00 ➝ $138.00High
i
8/6/2019BarclaysBoost Price TargetEqual Weight$108.00 ➝ $116.00High
i
8/6/2019Needham & Company LLCReiterated RatingBuy$125.00High
i
8/5/2019KeyCorpBoost Price TargetOverweight$114.00 ➝ $125.00High
i
4/15/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$103.00 ➝ $108.00Low
i
3/11/2019Needham & Company LLCReiterated RatingBuy$116.00Low
i
1/2/2019Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$100.00 ➝ $98.00Medium
i
11/27/2018UBS GroupInitiated CoverageBuy$115.00High
i
11/5/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$100.00 ➝ $105.00Low
i
10/15/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$95.00High
i
10/11/2018Morgan StanleyBoost Price TargetEqual Weight$95.00 ➝ $100.00Medium
i
7/31/2018Northcoast ResearchReiterated RatingBuy$104.00Low
i
7/30/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$97.00 ➝ $100.00Low
i
7/17/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$97.00 ➝ $115.00High
i
4/30/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$105.00 ➝ $106.00Medium
i
4/4/2018Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$85.00Low
i
Rating by Issac Ro at Goldman Sachs Group Inc
1/26/2018Needham & Company LLCReiterated RatingBuyLow
i
1/18/2018KeyCorpReiterated RatingBuy$97.00Low
i
1/16/2018Needham & Company LLCReiterated RatingPositive ➝ Buy$90.00 ➝ $105.00Medium
i
1/10/2018BarclaysReiterated RatingBuy$100.00Low
i
1/3/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$94.00High
i
1/2/2018Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
i
12/21/2017KeyCorpReiterated RatingBuy$94.00Low
i
11/29/2017Stifel NicolausReiterated RatingBuy$92.00Low
i
11/22/2017Bank of AmericaReiterated RatingHoldN/A
i
11/6/2017BarclaysBoost Price TargetOverweight$86.00 ➝ $90.00N/A
i
11/6/2017Stifel NicolausBoost Price TargetBuy$84.00 ➝ $85.00N/A
i
11/6/2017Needham & Company LLCLower Price TargetBuy$93.00 ➝ $90.00N/A
i
11/5/2017KeyCorpReiterated RatingBuy$82.00 ➝ $89.00N/A
i
10/17/2017KeyCorpReiterated RatingBuy$82.00N/A
i
7/30/2017Stifel NicolausReiterated RatingBuy$84.00Low
i
7/28/2017Cantor FitzgeraldSet Price TargetHold$86.00Low
i
Rating by Travis Steed at Cantor Fitzgerald
7/28/2017Needham & Company LLCLower Price TargetBuy$95.00 ➝ $93.00Low
i
6/30/2017Morgan StanleyBoost Price TargetOverweight$85.00 ➝ $90.00Low
i
6/29/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$95.00Low
i
6/29/2017Cantor FitzgeraldInitiated CoverageNeutral ➝ Neutral$86.00Low
i
6/9/2017BarclaysBoost Price TargetOverweight ➝ Overweight$80.00 ➝ $86.00Low
i
5/1/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$70.00 ➝ $84.00Low
i
5/1/2017BarclaysBoost Price TargetBuy$75.00 ➝ $80.00Low
i
4/19/2017BarclaysBoost Price TargetOverweight$70.00 ➝ $75.00Low
i
2/8/2017BarclaysInitiated CoverageOverweight$70.00N/A
i
1/23/2017Stifel NicolausInitiated CoverageBuy$70.00N/A
i
6/23/2016KeyCorpReiterated RatingBuy$59.00N/A
i
Rating by Matthew Mishan at KeyCorp
6/16/2016Morgan StanleyUpgradeEqual Weight ➝ Overweight$54.00 ➝ $62.00N/A
i
Rating by David Lewis at Morgan Stanley
5/3/2016Morgan StanleyReiterated RatingHoldN/A
i
Rating by David Lewis at Morgan Stanley
5/2/2016Bank of AmericaReiterated RatingBuy$69.00N/A
i
4/8/2016Goldman Sachs GroupBoost Price Target$52.00 ➝ $55.00N/A
i
3/23/2016Morgan StanleyReiterated RatingHold$54.00N/A
i
1/21/2016KeyCorpUpgradeSector Weight ➝ Overweight$59.00N/A
i
12/16/2015Northcoast ResearchUpgradeNeutral ➝ BuyN/A
i
(Data available from 10/25/2015 forward)
Hill-Rom logo
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as blood pressure, physical assessment, vital signs monitoring, diagnostic cardiopulmonary, diabetic retinopathy screening, and thermometry products; and respiratory health products comprising Vest System, VitalCough System, MetaNeb System, and Monarch systems to assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include surgical tables, lights, and pendants; positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables; and operating room surgical safety and accessory products, which comprise scalpels and blades, light handle systems, skin markers, and other disposable products. Further, it is involved in the sales and rental of products to acute and extended care facilities through direct sales force and distributors; sales and rental of products directly to patients in the home; and sales to primary care facilities through distributors. Additionally, the company offers continuum of clinical care, including acute care and primary care, as well as clinical research organizations. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $92.38
$90.88
$92.46

50 Day Range

MA: $86.57
$81.17
$92.06

52 Week Range

Now: $92.38
$72.29
$117.68

Volume

382,443 shs

Average Volume

638,586 shs

Market Capitalization

$6.15 billion

P/E Ratio

29.80

Dividend Yield

0.97%

Beta

0.63